Neuraxis Inc (NRXS)

Currency in USD
2.470
+0.140(+6.01%)
Closed·
2.340-0.130(-5.26%)
·
NRXS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
NRXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2802.485
52 wk Range
1.3306.200
Key Statistics
Prev. Close
2.33
Open
2.31
Day's Range
2.28-2.485
52 wk Range
1.33-6.2
Volume
37.01K
Average Volume (3m)
125.58K
1-Year Change
-19.81%
Book Value / Share
0.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NRXS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.875
Upside
+137.85%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Neuraxis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Neuraxis Inc Company Profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Neuraxis Inc Earnings Call Summary for Q2/2025

  • Neuraxis reported 46% YoY revenue growth to $894,000 in Q2 2025, with gross margin at 83.6%. Stock rose 2.47% pre-market.
  • FDA expanded indication for Neuraxis' treatment, potentially doubling addressable market. Company focuses on insurance coverage and sales force growth.
  • Operating loss reduced to $1.7M from $2.2M. $6M cash on hand, including $5M from equity financing.
  • Company targets cash flow breakeven, expects continued revenue growth in H2 2025. New CPT code effective January 2026 to drive adoption.
  • CEO Brian Karako: 'We are still in the very early stages of what we expect to be substantial top and bottom line growth.'
Last Updated: 12/08/2025, 15:18
Read Full Transcript

Compare NRXS to Peers and Sector

Metrics to compare
NRXS
Peers
Sector
Relationship
P/E Ratio
−3.1x−3.9x−0.6x
PEG Ratio
−0.05−0.100.00
Price/Book
5.7x3.5x2.6x
Price / LTM Sales
7.6x3.7x3.3x
Upside (Analyst Target)
137.9%34.2%38.0%
Fair Value Upside
Unlock5.5%4.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 5.875
(+137.85% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.22 / -0.25
Revenue / Forecast
894.00K / --
EPS Revisions
Last 90 days

NRXS Income Statement

People Also Watch

3.3800
SNGX
+0.60%
4.15
CTKB
+3.49%
1.18
KAPA
+0.85%
7.170
AMPX
+5.60%
5.67
REPL
+1.25%

FAQ

What Stock Exchange Does Neuraxis Trade On?

Neuraxis is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Neuraxis?

The stock symbol for Neuraxis is "NRXS."

What Is the Neuraxis Market Cap?

As of today, Neuraxis market cap is 23.76M.

What Is Neuraxis's Earnings Per Share (TTM)?

The Neuraxis EPS (TTM) is -1.05.

From a Technical Analysis Perspective, Is NRXS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Neuraxis Stock Split?

Neuraxis has split 0 times.

How Many Employees Does Neuraxis Have?

Neuraxis has 21 employees.

What is the current trading status of Neuraxis (NRXS)?

As of 24 Aug 2025, Neuraxis (NRXS) is trading at a price of 2.47, with a previous close of 2.33. The stock has fluctuated within a day range of 2.28 to 2.49, while its 52-week range spans from 1.33 to 6.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.